Quality-Adjusted Life Year (QALY)
Exploring the willingness to pay for a quality-adjusted life-year in the state of Penang, Malaysia
9
Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?
8
Headroom beyond the quality adjusted life year
11
Willingness to pay for one quality-adjusted life year in Iran
10
MRI-guided pulmonary vein isolation for atrial fibrillation: what is good enough? An early health technology assessment
7
Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study
9
Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case
7
Cost effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU acquired candidemia among patients with sepsis: a model simulation
11
An economic evaluation of an augmented cognitive behavioural intervention vs. computerized cognitive training for post-stroke depressive symptoms
12
Is an ounce of prevention worth a pound of cure? : Estimates of the impact of English public health grant on mortality and morbidity
36
Clinical effectiveness and cost effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation
16
Update: Eliciting societal preferences for weighting QALY's according to burden of illness, size of gain and end of life
38
Cost Utility Analysis of Radiographic Screening for an Orbital Foreign Body before MR Imaging
8
Where’s WALY? : A proof of concept study of the ‘wellbeing adjusted life year’ using secondary analysis of cross sectional survey data
10
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis
7
Quality of life in the five years after intensive care: a cohort study
12
Problems and solutions in calculating quality-adjusted life years (QALYs)
8
METFORMIN THE TIME TESTED TRUSTWORTHY MEDICINE IN THE MANAGEMENT OF TYPE 2 DIABETES
18
Cost-effectiveness of ablation of ventricular tachycardia in ischaemic cardiomyopathy: limitations in the trial evidence base
8
A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal
8